Why Madrigal Pharma Boasts 133% Upside
November 19, 2018 at 08:23 AM EST
Earlier this month, Madrigal announced its Q3 earnings results, and the effect of the earlier stock offerings was clear. The company reported operating expenses of $11.3 million, R&D expenses of $6.2 million, and a $19.2 million cash burn.
